No Prescription |
 |
 | ||
|
Calcitriol Generic Rocaltrol |
|
| ||
No Prescription » Prescription Drugs 3 » Calcitriol Generic Rocaltrol Indications1. Established postmenopausal osteoporosis. 2. Renal osteodystrophy in patients with chronic renal failure particularly those undergoing haemodialysis. 3. Secondary hyperparathyroidism in patients with moderate to severe chronic renal failure (pre-dialysis). 4. Postsurgical hypoparathyroidism. 5. Idiopathic hypoparathyroidism. 6. Pseudohypoparathyroidism. 7. Vitamin D-dependent rickets. 8. Hypophosphataemic vitamin D-resistant rickets. 9. Prevention of corticosteroid induced osteoporosis. Buy Calcitriol Generic Rocaltrol and other Prescription Drugs 3 products online at Medstore. Buy Online at Medstore - Click Here!
About Calcitriol Generic Rocaltrol: Product Type: Prescription Drugs 3 Calcitriol( Generic Rocaltrol ) Calcitriol (Generic Rocaltrol) Generic Rocaltrol 0.25mcg 90(3 x 30) Capsules 30 Capsules 0.5mcg 100 Capsules 200(2 x 100) Caps Generic Rocaltrol Calcitriol
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
